Stocks and Investing Stocks and Investing
Thu, January 14, 2021
Wed, January 13, 2021
Tue, January 12, 2021
Mon, January 11, 2021

Colin Bristow Downgraded (SRPT) to Hold on, Jan 11th, 2021


Published on 2024-10-27 15:11:16 - WOPRAI, Colin Bristow
  Print publication without navigation


Colin Bristow of UBS, Downgraded "Sarepta Therapeutics, Inc." (SRPT) to Hold on, Jan 11th, 2021.

Colin has made no other calls on SRPT in the last 4 months.



There are 8 other peers that have a rating on SRPT. Out of the 8 peers that are also analyzing SRPT, 3 agree with Colin's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Danielle Brill of "Raymond James" Downgraded from Buy to Hold on, Friday, January 8th, 2021
  • Martin Auster of "Credit Suisse" Maintained at Hold with Decreased Target to $73 on, Friday, January 8th, 2021
  • Matthew Harrison of "Morgan Stanley" Downgraded from Buy to Hold and Decreased Target to $95 on, Friday, January 8th, 2021


These are the ratings of the 5 analyists that currently disagree with Colin


  • Anupam Rama of "JP Morgan" Downgraded from Buy to Sell and Held Target at $96 on, Friday, January 8th, 2021
  • Chad Messer of "Needham" Maintained at Strong Buy with Decreased Target to $166 on, Friday, January 8th, 2021
  • Joseph Schwartz of "SVB Leerink" Maintained at Buy with Decreased Target to $125 on, Friday, January 8th, 2021
  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy and Held Target at $135 on, Friday, January 8th, 2021
  • Joel Beatty of "Citigroup" Maintained at Strong Buy with Increased Target to $190 on, Tuesday, September 15th, 2020